glp-1 and dual glp-1/gip receptor agonists PDF] The Effects of Agonism on Glucagon Secretion—A Review Fair Allocation of GLP-1 and

JAMA 2018

Randomised controlled trial of fish oil supplementation on responsiveness to resistance exercise training in sarcopenic older women

What is already known on this topic Glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter-2 (SGLT-2) inhibitors reduce the risk of cardiovascular and renal events in patients with type 2 diabetes These drug classes are increasingly used in combination when previous therapy with other antihyperglycaemic drugs fails Whether the combined use of these drug classes results in improved cardiovascular and renal outcomes in the real world setting, compared with the use of either drug class alone, remains unclear What this study adds This population based cohort study aimed at emulating a randomised controlled trial The combined use of a GLP-1 receptor agonist and an SGLT-2 inhibitor was associated with a lower risk of cardiovascular and serious renal events, compared with either drug class alone These findings highlight the potential benefit of combining these two effective drug classes in preventing cardiovascular and renal events in the treatment of type 2 diabetes Data availability statement This study is based on data from the Clinical Practice Research Datalink obtained under license from the UK Medicines and Healthcare products Regulatory Agency

55,56 These findings prompted regulatory safety communications and heightened surveillance regarding pancreatic safety

Acute Inflammation is central to in-vivo responses to a wide range of challenges including viral and bacteriological infections, and to host repair processes

This includes reduced food preoccupation or food noise, reduced emotional eating, less external eating (i.e., eating that responds to external triggers, irrespective of satiety), and fewer binge eating episodes [52,140]